$131 Million is the total value of Burrage Capital Management LLC's 25 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 59.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EPZM | Sell | EPIZYME INC | $10,105,000 | -15.5% | 930,467 | -7.2% | 7.70% | -18.4% |
| PTCT | Sell | PTC THERAPEUTICS INC | $9,831,000 | +21.2% | 161,083 | -7.2% | 7.49% | +17.0% |
| NEO | Sell | NEOGENOMICS INC | $9,625,000 | +35.4% | 178,777 | -7.2% | 7.34% | +30.7% |
| ISEE | Sell | IVERIC BIO INC | $9,592,000 | +13.7% | 1,388,136 | -7.2% | 7.31% | +9.8% |
| PLX | New | PROTALIX BIOTHERAPEUTICS INC | $8,967,000 | – | 2,470,332 | +100.0% | 6.83% | – |
| TPTX | Sell | TURNING POINT THERAPEUTICS I | $8,832,000 | +29.4% | 72,484 | -7.2% | 6.73% | +25.0% |
| MEIP | Buy | MEI PHARMA INC | $8,464,000 | -10.7% | 3,205,938 | +5.5% | 6.45% | -13.8% |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $8,237,000 | – | 1,105,673 | +100.0% | 6.28% | – |
| YMAB | Sell | Y-MABS THERAPEUTICS INC | $5,692,000 | +20.5% | 114,962 | -6.6% | 4.34% | +16.4% |
| INSM | Sell | INSMED INC | $5,145,000 | -3.2% | 154,562 | -6.6% | 3.92% | -6.6% |
| CYTK | Sell | CYTOKINETICS INC | $5,113,000 | -10.8% | 246,036 | -7.1% | 3.90% | -13.9% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $4,654,000 | +100.9% | 81,357 | +5.9% | 3.55% | +93.9% |
| AUPH | Sell | AURINIA PHARMACEUTICALS INC | $4,652,000 | -12.9% | 336,384 | -7.2% | 3.55% | -15.9% |
| FREQ | Sell | FREQUENCY THERAPEUTICS INC | $4,395,000 | +70.5% | 124,650 | -7.1% | 3.35% | +64.7% |
| ADCT | Sell | ADC THERAPEUTICS SA | $4,028,000 | -9.5% | 125,850 | -6.7% | 3.07% | -12.6% |
| INZY | New | INOZYME PHARMA INC | $3,525,000 | – | 170,796 | +100.0% | 2.69% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $3,486,000 | – | 64,079 | +100.0% | 2.66% | – |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $3,184,000 | +37.7% | 271,926 | -6.8% | 2.43% | +32.9% |
| CRNX | Sell | CRINETICS PHARMACEUTICALS IN | $3,162,000 | -16.4% | 224,129 | -7.1% | 2.41% | -19.3% |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $2,822,000 | – | 161,628 | +100.0% | 2.15% | – |
| MRUS | Sell | MERUS N V | $2,291,000 | +36.2% | 130,683 | -6.8% | 1.75% | +31.5% |
| GTHX | Sell | G1 THERAPEUTICS INC | $2,118,000 | -19.8% | 117,708 | -48.5% | 1.61% | -22.6% |
| AVRO | New | AVROBIO INC | $2,031,000 | – | 145,715 | +100.0% | 1.55% | – |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $1,118,000 | – | 34,891 | +100.0% | 0.85% | – |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $134,000 | -23.4% | 15,006 | 0.0% | 0.10% | -26.1% | |
| CALT | Exit | CALLIDITAS THERAPEUTICS ABsponsered ads | $0 | – | -11,034 | -100.0% | -0.21% | – |
| ADRO | Exit | ADURO BIOTECH INC | $0 | – | -135,898 | -100.0% | -0.26% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -39,189 | -100.0% | -0.56% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -188,182 | -100.0% | -1.35% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -116,405 | -100.0% | -2.53% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -200,000 | -100.0% | -2.60% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -330,549 | -100.0% | -3.85% | – |
| KIDS | Exit | ORTHOPEDIATRICS CORP | $0 | – | -171,607 | -100.0% | -6.22% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -332,546 | -100.0% | -9.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EPIZYME INC COM | 7 | Q2 2021 | 15.9% |
| NeoGenomics Inc | 7 | Q2 2021 | 8.7% |
| OrthoPediatrics Corp | 7 | Q2 2021 | 7.3% |
| Y-MABS THERAPEUTICS INC COM | 7 | Q2 2021 | 4.3% |
| CRINETICS PHARMACEUTICALS INC COM | 7 | Q2 2021 | 5.6% |
| G1 THERAPEUTICS INC COM | 7 | Q2 2021 | 7.3% |
| PTC THERAPEUTICS INC COM | 6 | Q1 2021 | 8.0% |
| CYTOKINETICS INC COM NEW | 6 | Q2 2021 | 4.9% |
| TURNING PT THERAPEUTICS INC COM | 6 | Q2 2021 | 6.7% |
| APELLIS PHARMACEUTICALS INC COM | 6 | Q1 2021 | 3.5% |
View Burrage Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.Sold out | July 30, 2021 | 0 | 0.0% |
| IVERIC bio, Inc. | February 14, 2020 | 10 | 3.4% |
View Burrage Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| SC 13G/A | 2021-07-30 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-12 |
| SC 13G | 2021-02-12 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
View Burrage Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.